Terms of reference - CLG
Terms of reference - CLG
Embedded Files
Terms of Reference
Terms of Reference
1. Role of the Group
1. Role of the Group
The LCRN Clinical Director shall convene the LCRN Clinical Leaders Group.
The LCRN Clinical Director shall convene the LCRN Clinical Leaders Group.
The role of this Group is to advise the LCRN Leadership Team with particular respect to:
The role of this Group is to advise the LCRN Leadership Team with particular respect to:
(a) changes in national policies and priorities in relation to health and care research and implications for the LCRN;
(a) changes in national policies and priorities in relation to health and care research and implications for the LCRN;
(b) the LCRN study portfolio and the balance of the portfolio across Specialties, sites, patient groups and study composition;
(b) the LCRN study portfolio and the balance of the portfolio across Specialties, sites, patient groups and study composition;
(c) equality, diversity and inclusion in relation to LCRN studies and strategies to expand research participation;
(c) equality, diversity and inclusion in relation to LCRN studies and strategies to expand research participation;
(d) resource allocations;
(d) resource allocations;
(e) general clinical intelligence and advice to support LCRN research delivery.
(e) general clinical intelligence and advice to support LCRN research delivery.
2. Membership of the Group
2. Membership of the Group
The membership of the group shall include the Clinical Director (Chair) and / or deputy Clinical Director, Chief Operating Officer and / or Deputy Chief Operating Officer, the LCRN Clinical Research Specialty Leads.
The membership of the group shall include the Clinical Director (Chair) and / or deputy Clinical Director, Chief Operating Officer and / or Deputy Chief Operating Officer, the LCRN Clinical Research Specialty Leads.
Additional membership from the Lead Nurse / AHP and R&D Managers group will be reviewed on a yearly basis to allow for rotation.
Additional membership from the Lead Nurse / AHP and R&D Managers group will be reviewed on a yearly basis to allow for rotation.
3. Business
3. Business
The Group will:
The Group will:
● Include a standing agenda item at the beginning of each meeting for members to declare conflict of interests
● Include a standing agenda item at the beginning of each meeting for members to declare conflict of interests
● Advise the LCRN Executive Group with particular respect to:
● Advise the LCRN Executive Group with particular respect to:
● Clinical implications of national policy at the local level;
● Clinical implications of national policy at the local level;
● The balance of the LCRN portfolio across specialties, sites, patient groups and study composition;
● The balance of the LCRN portfolio across specialties, sites, patient groups and study composition;
● Resource allocations;
● Resource allocations;
● Other clinical intelligence and advice to support LCRN research delivery
● Other clinical intelligence and advice to support LCRN research delivery
● Strategic direction of NIHR CRN in the South West
● Strategic direction of NIHR CRN in the South West
And will also:
And will also:
● Liaise with the Operational Management and Local Clinical Research Specialty Groups regarding performance issues, resource allocation, the balance of the LCRN portfolio and availability of opportunities in the LCRN area for all patients and members of the public to participate in research;
● Liaise with the Operational Management and Local Clinical Research Specialty Groups regarding performance issues, resource allocation, the balance of the LCRN portfolio and availability of opportunities in the LCRN area for all patients and members of the public to participate in research;
● support identification and development of research communities of practice within the LCRN area.
● support identification and development of research communities of practice within the LCRN area.
4. Voting
4. Voting
The Group is expected to make decisions by consensus. In formulating strategy and making decisions, the Group should always have regard to the best interests of the LCRN Partners as a whole, and not the specific interests of any one party or sector.
The Group is expected to make decisions by consensus. In formulating strategy and making decisions, the Group should always have regard to the best interests of the LCRN Partners as a whole, and not the specific interests of any one party or sector.
Should voting be required, only the voting members shall vote.
Should voting be required, only the voting members shall vote.
The Chair shall not have a casting vote.
The Chair shall not have a casting vote.
No individual member or combination of members shall have a power of veto.
No individual member or combination of members shall have a power of veto.
5. Quoracy
5. Quoracy
A quorum will be the CRN: SWP CD or Deputy CD and COO or Deputy COO, three of the five CRLs.
A quorum will be the CRN: SWP CD or Deputy CD and COO or Deputy COO, three of the five CRLs.
6. Meeting Arrangements
6. Meeting Arrangements
● The LCRN Management Team shall provide the secretariat function.
● The LCRN Management Team shall provide the secretariat function.
● The agenda will be set by the Chair in consultation with group members.
● The agenda will be set by the Chair in consultation with group members.
● Agenda and papers will be circulated five working days in advance of the meeting.
● Agenda and papers will be circulated five working days in advance of the meeting.
● Meetings will be held monthly on a Wednesday morning virtually via teams - Link which will be forwarded in the meeting request. Should service need dictate that a face to face meeting is required then a venue will be sourced at either Exeter or Plymouth.
● Meetings will be held monthly on a Wednesday morning virtually via teams - Link which will be forwarded in the meeting request. Should service need dictate that a face to face meeting is required then a venue will be sourced at either Exeter or Plymouth.
Review Date: These ToRs will be reviewed April 2024
Review Date: These ToRs will be reviewed April 2024
Page updated
Report abuse